Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …

Recent insights into the molecular pathogenesis of colorectal cancer (CRC) have given rise
to specific targetdirected therapies, including monoclonal antibodies (mAb) against …

The development of EGFR small-molecule inhibitors has provided significant benefit for the
affected patient population. Unfortunately, current inhibitors are no curative therapy, and …

Lung cancer causes the highest mortality compared to other cancers in the world according
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB
receptor family that is abnormally activated in many epithelial tumors. The aberrant …

Acquired resistance to targeted therapy in epidermal growth factor receptor (EGFR)–mutant
lung cancer represents a valuable model for considering strategies of overcoming different …

Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in
patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or …

Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients
for almost a decade. Current knowledge on their role in the first or subsequent lines of …

The EGFR has been targeted through the development of selective tyrosine kinase inhibitors
(TKIs) that have proven effective in a subset of non-small cell lung cancer (NSCLC) patients …

Gefitinib and erlotinib, which are epidermal growth factor receptor‐(EGFR‐) specific tyrosine
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …